SCHEMBL6035543

SCHEMBL6035543

CCOC(=O)c1c[nH]nc1C(CC)CC

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.45
MEN1 O00255 3/20 0.45
TSHR P16473 1/20 0.44
ALDH1A1 P00352 5/20 0.43
NPC1 O15118 1/20 0.41
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 2/20 0.41
LMNA P02545 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CLEC4M Q9H2X3 1/20 0.40
PDE4D Q08499 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
KDM4E B2RXH2 2/20 0.40
HSD17B10 Q99714 1/20 0.39
GABRA1 P14867 1/20 0.39
GABRB2 P47870 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25660006 0.92 KMT2A (0.42) KMT2AMEN1TSHRALDH1A1NPC1
SCHEMBL6034572 0.86 KMT2A (0.44) KMT2AMEN1TSHRALDH1A1NPC1
SCHEMBL4294216 0.85 KMT2A (0.46) KMT2AMEN1TSHRALDH1A1NPC1
SCHEMBL622895 0.84 KMT2A (0.45) KMT2AMEN1TSHRALDH1A1NPC1
SCHEMBL15166583 0.81 KMT2A (0.43) KMT2AMEN1TSHRALDH1A1NPC1
SCHEMBL6035126 0.80 KDM4E (0.42) KMT2AMEN1TSHRALDH1A1NPC1
SCHEMBL263628 0.78 TSHR (0.52) KMT2AMEN1TSHRALDH1A1MAPT
SCHEMBL2147241 0.76 KMT2A (0.50) KMT2AMEN1TSHRALDH1A1MAPT
SCHEMBL3376695 0.76 KDM4E (0.51) KMT2AMEN1TSHRALDH1A1POLB
SCHEMBL161443 0.76 KMT2A (0.50) KMT2AMEN1TSHRALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed
EP-1513817-A1 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY Takeda Pharmaceutical Company Limited (JP) 2005-03-16 EP disclosed
WO-2003099793-A9 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL (JP) 2005-02-10 WO disclosed
WO-2003099793-A1 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 KMT2A 1706/4885MEN1 2048/4885TSHR 910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.